Phathom Pharmaceuticals Inc (NAS:PHAT)

Q4 2025 Phathom Pharmaceuticals Inc Earnings Call Transcript

Feb 26, 2026 / 01:00 PM GMT

Release Date Price: $13.56 (+9.89%)

Transcript 10-K8-K

Key Points

Positve

Phathom Pharmaceuticals Inc (PHAT) reported a successful Q4, delivering on expectations for both revenue and cash operating expenses, coming in at the better end of their guided ranges.
The company achieved a 217% year-over-year growth in net revenues for the full year 2025, reaching $175.1 million.
Phathom Pharmaceuticals Inc (PHAT) has taken significant steps to enhance its capital structure, including reducing interest expenses and modifying outstanding term loan obligations.
The company is on track to achieve operating profitability by Q3 2026 and cash flow positivity in 2027.
Phathom Pharmaceuticals Inc (PHAT) has a nearly full-strength sales organization, with more than 285 of their 300 sales positions filled, and is seeing clear signs that their GI strategy is working.

Negative

The company faces typical seasonality challenges, with Q1 expected to be the weakest quarter due to winter storms and plan resets.
Phathom Pharmaceuticals Inc (PHAT) does not anticipate a fundamental change in broad Medicare coverage, which may limit access for some patients.
The company acknowledges that the majority of prescriptions come from prior patients, indicating a reliance on existing customers for growth.
There is a potential risk of increased competition in the PCA space, with other companies developing similar products.
Phathom Pharmaceuticals Inc (PHAT) has not yet made decisions on pursuing additional indications beyond EOE for their product, which may limit future growth opportunities.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PHAT.OQ - Phathom Pharmaceuticals Inc
Q4 2025 Phathom Pharmaceuticals Inc Earnings Call
Feb 26, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to Fathom Pharmaceuticals 4th quarter and full year 2025 earnings results call. At this time, all participants are in the listen-only mode. After the presentation, there will be a question-and-answer session.

To ask a question, please press 11 on your telephone keypad. Please be advised that today's call is being recorded. With that, I would like to turn the call over to Eric Sciarrelli, Fathom's head of investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you operator. Hello everyone and thank you for

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.